Study of RJMty19 for hard-to-treat lupus
Part of Immune system & allergy, Skin clinical trials.
This study tests a new cell therapy called RJMty19 for people with lupus that has not responded to standard treatments. The therapy targets and helps remove overactive B cells to calm the immune system and reduce lupus activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with systemic lupus erythematosus (SLE) that is active (score of 8 or more on a lupus activity scale) and is affecting your organs.
- Your lupus has not improved with at least two standard immunosuppressants and one biologic medicine, or you cannot take one of these due to side effects.
- You have adequate kidney, liver, heart, lung, and blood function as determined by standard lab tests.
- You have not had CAR-T therapy or other gene-modified cell therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a personalized cell therapy called CD19 CAR-T can help people with hard-to-treat lupus (SLE). The treatment uses your own immune cells that have been modified to attack faulty B cells, which are involved in lupus. It is for patients who have moderate to severe disease despite trying multiple standard treatments.
This study tests a new treatment called CD19 CAR-T, which reprograms your own immune cells to attack lupus. It is for people with active lupus that has not responded well to standard therapies.
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
This trial tests a quick-made CAR-T cell therapy for children and adults with active lupus who haven't gotten better with standard drugs. The goal is to see if targeting a protein called CD19 on certain immune cells can calm the disease.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.